Bradley is an associate in the litigation and enforcement practice group, where he represents clients in an array of government enforcement matters and complex civil disputes. Bradley’s practice includes government-initiated and internal investigations, complex civil litigation, and deal-related anti-corruption, anti-money laundering and litigation risk analyses. He has worked with clients in various industries including health care, biotechnology, private equity, and investment management. Bradley is also actively involved with the firm’s pro bono efforts and currently serves as an immigration team co-lead for Ropes & Gray's medical-legal partnership with the Dorchester House in Boston.
During law school, Bradley worked as a judicial intern to the Honorable Joseph F. Bianco of the U.S. Court of Appeals for the Second Circuit and the Honorable William G. Young of the U.S. District Court for the District of Massachusetts. Prior to law school, he worked as a paralegal at a white-collar litigation firm.
Experience
- Conducting internal investigation for global investment bank concerning compliance with SEC regulations.
- Conducting internal investigation for global packaging company assessing litigation risk from potential misconduct.
- Represents medical device company in qui tam False Claims Act dispute.
- Represented leading medical device company in antitrust investigation by the FTC.
- Represented major pharmaceutical manufacturer in a state attorney general consumer protection matter relating to the manufacturing and promotion of certain drugs.
- Advised large private equity firm on litigation risks in connection with multi-billion dollar acquisition of an animal health care company.
- Advised professional sports league on sports wagering legislation and related license application processes in various states.
- Represented technology sector executive in internal investigation by company’s board of directors concerning public disclosures.
- Regularly conducts pre-acquisition anti-corruption, anti-money laundering, and sanctions due diligence for large private equity firms